Pharmacokinetics of ganciclovir in haematopoietic stem cell transplantation recipients with or without renal impairment

    loading  Checking for direct PDF access through Ovid



We investigated the pharmacokinetics of ganciclovir in 12 haematopoietic stem cell transplantation (HSCT) recipients to evaluate the validity of a 50% reduction in the ganciclovir dosage for mild renal impairment.

Patients and methods

Ganciclovir at 5 mg/kg/day was pre-emptively infused in patients with estimated CLCR ≥ 70 mL/min (Group A), whereas the dose was reduced to 2.5 mg/kg/day in patients with CLCR between 50 and 70 mL/min (Group B).


The peak concentration was significantly higher in Group A (P < 0.01). However, the decrease in the plasma ganciclovir concentration was slower in Group B (P=0.09), and the AUC of all patients in both groups was distributed within a narrow range (25.6 ± 4.77 μg·h/mL), when two patients with exceptionally high AUC values were excluded.


A 50% reduction in ganciclovir appeared to be appropriate for patients with mild renal impairment. Measuring the ganciclovir concentration at 4 h after starting infusion may be adequate for evaluating AUC.

Related Topics

    loading  Loading Related Articles